{"id":"W4382513940","doi":"10.1097/01.hs9.0000936124.56965.24","title":"B08 IDECABTAGENE VICLEUCEL VERSUS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA: KARMMA-3 A PHASE 3 RANDOMIZED CONTROLLED TRIAL","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Daratumumab; Pomalidomide; Medicine; Lenalidomide; Regimen; Internal medicine; Dexamethasone; Ixazomib; Oncology; Multiple myeloma; Carfilzomib; Clinical endpoint; Randomized controlled trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001838543,0.0015585,0.002681182,0.0003653381,0.0004464702,0.001378655,0.0009313395,0.001710925,0.007383316],"category_scores_gemma":[0.001409527,0.0006355383,0.002595897,0.0004648188,0.000845967,0.001127158,0.0004356933,0.003355279,0.001101421],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000882078,"about_ca_system_score_gemma":0.001118518,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001040514,"about_ca_topic_score_gemma":0.002493141,"domain_scores_codex":[0.9994107,0.000294476,0.00003815757,0.0001238579,0.00004074151,0.00009203156],"domain_scores_gemma":[0.9991205,0.0002230309,0.0002588221,0.00007299891,0.00005662337,0.0002680254],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9799622,0.003957558,0.0005807902,0.0006628883,0.001299278,0.00003305995,0.00003644678,0.0002532075,0.001278858,0.00007215994,0.0009905264,0.01087296],"study_design_scores_gemma":[0.9627428,0.03381285,0.001734045,0.00004874231,0.0005299237,0.00004096587,0.00001489677,0.0003368244,0.000142819,0.0001106944,0.0004734602,0.00001213993],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9794748,0.01077486,0.0004597108,0.001005708,0.0005854461,0.003234515,0.00137655,0.0002104366,0.002878067],"genre_scores_gemma":[0.9871427,0.003196264,0.001097699,0.001605839,0.0004113372,0.003387189,0.001229688,0.00002807874,0.001901335],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007383316,"threshold_uncertainty_score":0.02469963,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02313725160101678,"score_gpt":0.3011518509707363,"score_spread":0.2780145993697196,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}